neotiv, a Magdeburg, Germany-based digital health startup, secured a seed funding from High-Tech Gründerfonds.
The amount of the deal was not disclosed.
Led by Chief Executive Officer Dr. Chris Rehse and dementia researcher Prof. Emrah Düzel, neotiv develops apps that are able to measure the psychological effects of Alzheimer’s disease in its early stage. In this way, the company brings the latest findings in the field of neurodegenerative disease research to mobile apps for private users, doctors and drug development.
The technology is based on memory tests that have been specially developed for this purpose in comprehensive scientific studies at national and international levels. The scores obtained in these tests indicate whether specific brain regions are functionally compromised. neotiv delivers a snapshot of a patient’s mental capacity and enables a long-term, high-frequency monitoring of memory. This type of monitoring enables a dynamic tailoring of possible preventative and therapeutic measures.
The app will help health-conscious individuals to optimize changes to their lifestyle in a preventative manner so as to reduce dementia-related risks in a targeted way. It will also enable doctors to detect changes brought on by Alzheimer’s and to monitor the course of treatment. Drug developers can also use the app to make a more efficient pre-selection of trial candidates according to the early stages of the disease.
The app also provides them with improved and high frequency monitoring of treatment effects.
A spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases (DZNE), neotiv is being supported in the launch of the product on the e-health market by the Flying Health Incubator in Berlin. Research work is also being monitored and supported through the Federal Ministry for Economic Affairs and Energy’s (BMWi) EXIST Transfer of Research programme.